Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta
®
in healthy subjects: A randomized, double‐blind trial
2020 ◽
Vol 42
(8)
◽
pp. 1508-1518.e1
◽
Keyword(s):
Keyword(s):
Keyword(s):
2019 ◽
Vol 12
(1)
◽
pp. 48-54
Keyword(s):
Keyword(s):